CTOs on the Move

Just. Biotherapeutics

www.justbiotherapeutics.com

 
Just. is an integrated design company focused on the technology of biotherapeutics, from molecule to manufacturing plant. We believe that technological innovation will accelerate biotherapeutic development and dramatically reduce the cost of these vital medicines.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Just. Biotherapeutics raised $15M on 09/20/2015

Similar Companies

IntegenX

IntegenX is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.

Process Environments

Process Environments is a League City, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seven Bridges

Seven Bridges is the industry-leading unified bioinformatics solutions company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, analytic tools, and services expertise are driving discovery and drug development at the world`s leading academic, biotechnology, government, hospitals, and pharmaceutical entities. Through our collaboration with the largest genomics projects, we connect the world`s biomedical information to enable the most efficient analysis at scale.

Passage Bio

Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.